Contact Us:

Andrew Lees, CEO

andypicDr. Andrew Lees, founder and Chief Scientific Officer of Fina Biosolutions, holds over 20 patents and is the author or co-author of more than 60 peer-reviewed papers. Dr. Lees holds a B.S. in Chemistry from Harvey Mudd College and a Ph.D. in Biophysics from The Johns Hopkins University. Conjugation chemistry (CDAP) developed by Dr. Lees is used by GlaxoSmithKline, the Serum Institute of India, the Chengdu Institute of Biological Products and others in their S. pneumonia and meningococcal conjugate vaccines.

In addition to directing Fina Biosolutions, Dr. Lees is an associate professor in the Department of Medicine at the Uniformed Services University of the Health Sciences and at the University of Maryland School of Medicine’s Center for Vaccine Development; he is also an affiliate at the University of Maryland Bioprocessing Scale-Up Facility. He teaches protein chromatography up through the post-graduate level, and is a frequent speaker on conjugation chemistry and biotech entrepreneurship.

When not in the lab Dr. Lees indulges his passion for cycling and uses his tricky past as a professional magician ( to enliven his seminars and lectures.



  • About FinaBio
    Characterization of Fina Biosolutions’ Amino-Dextran
  • About FinaBio


9430 Key West Ave., Suite 200
Rockville, MD 20850
877-346-2246 (877-FinaBio)
301-633-0464 (Andrew Lees, Scientific Director)

About Us

Fina Biosolutions, LLC was founded in 2006 by Dr. Andrew Lees with an initial focus on helping emerging market vaccine manufacturers learn to make affordable conjugate vaccines. FinaBio has since grown to offer a variety of bioconjugation and protein services. The company is located in the heart of Maryland’s biotechnology corridor.